Extended mortality results for ovarian cancer screening in the PLCO trial with median 15 years follow-up

Gynecologic Oncology

Volumn 143, Issue 2, 2016, Pages 270-275

  Pinsky, Paul F ^a   Yu, Kelly ^a   Kramer, Barnett S ^a   Black, Amanda ^a   Buys, Saundra S ^b   Partridge, Edward ^c   Gohagan, John ^d   Berg, Christine D ^a   Prorok, Philip C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SCREENING; CANCER SPECIFIC SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSVAGINAL ECHOGRAPHY; BLOOD; CLINICAL TRIAL; DIAGNOSTIC IMAGING; EARLY CANCER DIAGNOSIS; ECHOGRAPHY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; OVARIAN NEOPLASMS; VAGINA;

AGED; CA-125 ANTIGEN; EARLY DETECTION OF CANCER; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; ULTRASONOGRAPHY; VAGINA;

EID: 84995426666     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2016.08.334     Document Type: Article

References (13)

1. [1] Surveillance, Epidemiology and End Results (SEER), Cancer Statistic Review. http://seer.cancer.gov/csr/1975_2013/.
2. [2] Buys, S., Partridge, E., Black, A., et al. Effect of screening on ovarian cancer mortality. The prostate, lung, colorectal and ovarian cancer screening randomized controlled trial. JAMA 305 (2011), 2298–2303.
3. [3] Jacobs, I., Menon, U., Ryan, A., et al. Ovarian cancer screening and mortality in the UK collaborative trial of ovarian cancer screening (UKCTOCS): a randomized controlled trial. Lancet 387 (2016), 945–956.
4. [4] Buys, S.S., Partridge, E., Greene, M.H., et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screen of a randomized trial. Am. J. Obstet. Gynecol. 193 (2005), 1630–1639.
5. [5] Miller, A.B., Feld, R., Fontana, R., et al. Changes in and impact of the death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Rev. Recent Clin. Trials 10 (2015), 206–211.
6. [6] Pinsky, P.F., Zhu, C., Skates, S., et al. Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) Trial. Int. J. Cancer 132 (2012), 2127–2133.
7. [7] Murphy, S.A., Van Der Vaart, A.W., On profile likelihood. J. Am. Stat. Assoc. 95 (2000), 449–465.
8. [8] Kaplan, E.L., Meier, P., Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53 (1958), 457–481.
9. [9] Ma, G.K., Ladabaum, U., Personalizing colorectal cancer screening: a systematic review of models to predict risk of colorectal neoplasia. Clin. Gastroenterol. Hepatol. 202 (2014), 9–26.
10. [10] Pashayan, N., Guo, Q., Pharoah, P.D., Personalized screening for cancers: should we consider polygenic profiling. Perinat. Med., 10(6), 2013: Aug 1, 10.2217/pme.13.46.
11. [11] La Vecchia, C., Ovarian cancer: epidemiology and risk factors. Eur. J. Cancer Prev., 2015 (online first).
12. [12] Pearce, C.L., Stram, D.O., Ness, R.B., et al. Population distribution of lifetime risk of ovarian cancer in the United States. Cancer Epidemiol. Biomark. Prev. 24 (2015), 671–676.
13. [13] Drescher, C.W., Shah, C., Thorpe, J., et al. Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule. J. Clin. Oncol. 31 (2013), 387–392.